We previously highlighted the need for a third vaccine booster dose in patients with inflammatory bowel diseases (IBDs) treated with anti-TNF-α due to the sharper decline in their serologic response compared to patients not treated with anti-TNFα and healthy controls (HCs) [3,10,11,12,13]. Here, TNF is linked to inflammatory bowel disease.